Cardiovascular Disease in Patients with Familial Hypercholesterolemia

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Epidemiology, Lifestyle, and Cardiovascular Health".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 962

Special Issue Editors


E-Mail Website
Guest Editor
Cardiometabolic Center, Lipid Clinic, LA Apheresis Unit, Metropolitan Hospital, 15562 Athens, Greece
Interests: familial hypercholesterolemia and other genetic disease concerning lipid metabolism; postprandial lipemia; longevity syndrome

E-Mail Website
Guest Editor
First Department of Propaedeutic Internal Medicine, Medical School, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: dyslipidemia; diabetes; obesity; hypertension as well as acid-base and electrolyte abnormalities

E-Mail Website
Guest Editor
Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece
Interests: type 2 diabetes mellitus; sodium-glucose cotransporter-2 inhibitors; Impaired renal function; COVID-19 patients

Special Issue Information

Dear Colleagues,

Familial hypercholesterolemia (FH) is one of the most common genetic disorders, affecting millions of people worldwide, and is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C). Left untreated, FH dramatically increases the risk of premature cardiovascular disease (CVD), including heart attacks, strokes, and other atherosclerotic events. This inherited condition leads to accelerated atherosclerosis, a process in which fatty deposits build up in arteries, increasing the likelihood of serious cardiovascular complications early in life. Given the significant burden FH places on global health, a deeper understanding of its genetic causes, early diagnosis, and effective treatment strategies is urgently needed.

This Special Issue on “Cardiovascular Disease in Patients with Familial Hypercholesterolemia” will gather research that addresses the multifaceted challenges posed by FH, from genetic and molecular mechanisms to clinical management and emerging therapies. We invite contributions that explore the latest advancements in diagnostic approaches, risk assessment, therapeutic interventions—including pharmacological and lifestyle treatments—as well as long-term outcomes in FH patients. By fostering dialogue and collaboration within the medical and research communities, this special issue aims to contribute to more effective prevention and treatment strategies for cardiovascular disease in this high-risk population.

We look forward to your valuable contributions to this Special Issue.

Dr. Genovefa D. Kolovou
Prof. Dr. Evangelos Liberopoulos
Prof. Dr. Haralampos J. Milionis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • familial hypercholesterolemia
  • atherosclerosis
  • LDL cholesterol
  • genetic mutations
  • lipid-lowering therapies
  • premature heart disease
  • risk assessment
  • early diagnosis
  • pharmacological treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 547 KiB  
Article
Prevalence and Risk Factors for Atherosclerotic Cardiovascular Disease in 7704 Individuals: An Analysis from the Greek Registry for the Prevalence of Familial Hypercholesterolemia (GRegistry-FH)
by Genovefa Kolovou, Stamatis Makrygiannis, Christina Marvaki, Niki Pavlatou, Katerina Anagnostopoulou, Vasiliki Giannakopoulou, Georgios Goumas, Petros Kalogeropoulos, Vana Kolovou, Sotiria Limberi, Despina Perrea, Anastasios Tzenalis, Zeimpek Emre, Edison Jahaj, Zoi Kasiara, Ilias Giannakoulis, Ioannis Tsolakoglou, Olga Kadda, Nikolaos Tsaloukidis, Rafailia Koulaxidou, Aikaterini Marvaki, Stefanos Foussas, Andreas Melidonis, Giannis Hoursalas, Charalambos Vlachopoulos, Niki Katsiki, Haralampos Milionis, Evaggelos Liberopoulos and Helen Bilianouadd Show full author list remove Hide full author list
J. Cardiovasc. Dev. Dis. 2024, 11(12), 411; https://doi.org/10.3390/jcdd11120411 - 23 Dec 2024
Viewed by 774
Abstract
The intention of this study was to profile the cohort from the Greek Registry for the prevalence of Familial Hypercholesterolemia (GRegistry-FH) by estimating the prevalence of coronary artery disease (CAD), myocardial infarction (MI), stroke, dyslipidemia, arterial hypertension, diabetes mellitus (DM), pre-DM, smoking, abnormal [...] Read more.
The intention of this study was to profile the cohort from the Greek Registry for the prevalence of Familial Hypercholesterolemia (GRegistry-FH) by estimating the prevalence of coronary artery disease (CAD), myocardial infarction (MI), stroke, dyslipidemia, arterial hypertension, diabetes mellitus (DM), pre-DM, smoking, abnormal thyroid function (ATF), and lipid values. The GRegistry-FH is a prospective study involving door-to-door interviews conducted by trained interviewers. Overall, 7704 individuals aged ≥18 years, randomly selected from all the regions of Greece, participated. The prevalence of atherosclerotic cardiovascular disease (ASCVD) was 13.9% (CAD 6%, MI 3.2%, stroke 4.7%). Treated hypercholesterolemia was present in 20.1%, arterial hypertension in 24%, and DM in 11.3% individuals (25.5% had pre-DM). The prevalence of smoking was 37.9% (29% current) and the prevalence of ATF was 13.1% (hypothyroidism 11.3%). A family history of ASCVD was reported by 60.5% (CAD 32.2%, stroke 28.3%). The mean (SD) lipid values in mg/dL were as follows: total cholesterol of 201.8 (41.5), low-density lipoprotein cholesterol of 126.3 (30.1), high-density lipoprotein cholesterol of 51.9 (12.5), and triglycerides of 135.9 (64.7). The GRegistry-FH highlights the significant prevalence of ASCVD and its risk factors among Greek adults, indicating a pressing need for early detection and management strategies to mitigate ASCVD burden. This nationwide registry serves as a crucial tool for guiding public health policies and personalized preventive measures (NCT03140605). Full article
(This article belongs to the Special Issue Cardiovascular Disease in Patients with Familial Hypercholesterolemia)
Show Figures

Figure 1

Back to TopTop